Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

The Lymphoma Channel on VJHemOnc is an independent medical education platform, supported with funding from AstraZeneca (Diamond), BMS (Gold), Johnson & Johnson (Gold), Takeda (Silver) and Galapagos (Bronze). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.

Share this video  

EHA 2022 | Updates on tafasitamab for the treatment of DLBCL

Wojciech Jurczak • 11 Jun 2022
EHA 2022
Diffuse Large B-Cell Lymphoma Lymphoma Non-Hodgkin Lymphoma Antibodies Bendamustine CAR-T Lenalidomide Polatuzumab vedotin Rituximab Tafasitamab

In this video, Wojciech Jurczak, MD, PhD, Jagiellonian University, Krakow, Poland, talks on tafasitamab for the treatment of diffuse large B-cell lymphoma (DLBCL), highlighting a study which demonstrated the efficacy of patients treated with tafasitamab plus lenalidomide compared to patients treated with polatuzumab vedotin and CAR-T cell therapy. This interview took place at the European Hematology Association (EHA) Congress 2022 held in Vienna, Austria.

More from Wojciech Jurczak

Treating R/R CLL: the value of BTKis and venetoclax 1:59
Treating R/R CLL: the value of BTKis and venetoclax
Wojciech Jurczak • 27 Sep 2024
Improving the long-term safety of CLL treatment 0:58
Improving the long-term safety of CLL treatment
Wojciech Jurczak • 27 Sep 2024
The potential of adding anti-CD20 antibodies to acalabrutinib and venetoclax in CLL 1:21
The potential of adding anti-CD20 antibodies to acalabrutinib and venetoclax in CLL
Wojciech Jurczak • 27 Sep 2024
Long-term follow-up of tafasitamab and lenalidomide in R/R DLBCL 1:35
Long-term follow-up of tafasitamab and lenalidomide in R/R DLBCL
Wojciech Jurczak • 10 Jun 2023

Related Videos

Long-term follow-up results from ELM-2: odronextamab in R/R FL 8:08
Long-term follow-up results from ELM-2: odronextamab in R/R FL
Gottfried von Keudell • 18 Sep 2025
The efficacy of glofitamab in patients with heavily pre-treated R/R MCL 1:24
The efficacy of glofitamab in patients with heavily pre-treated R/R MCL
Tycel Phillips • 5 Sep 2025
Bringing clinical trials to the community: current approaches at Sarah Cannon Research Institute 1:01
Bringing clinical trials to the community: current approaches at Sarah Cannon Research Institute
Krish Patel • 4 Sep 2025
Bispecifics and CAR T-cell therapy in lymphoma: sequencing strategies and considerations 1:52
Bispecifics and CAR T-cell therapy in lymphoma: sequencing strategies and considerations
Tycel Phillips • 5 Sep 2025
The content of VJHemOnc is intended for healthcare professionals